Up to ~24%
Average body-weight reduction observed at the highest dose over 48 weeks in phase 2 research of the triple-agonist class.
Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. NEJM, 2023.
The protocol
One molecule, three pathways
Reta1 is built on a triple-agonist peptide — the most studied new class in metabolic medicine. Here's exactly how it works and what arrives at your door.
The protocol
One molecule. Three pathways.
A triple-agonist engages the GLP-1, GIP and glucagon receptors together — addressing appetite, insulin response and energy expenditure in a single weekly dose.
01
GLP-1
Appetite & fullness
Slows gastric emptying and signals satiety, so you eat less without willpower battles.
02
GIP
Insulin response
Improves how your body handles glucose and may ease the side-effect burden of GLP-1 alone.
03
Glucagon
Energy expenditure
Adds a metabolic lever that can increase the calories you burn at rest.
Everything you need, in one box
No prescriptions to chase, no supplies to source. Your complete protocol arrives ready to start.
Your peptide protocol
Pharmaceutical-grade, cGMP-manufactured, and third-party tested for purity before it ships.
Everything to dose
Pre-measured supplies, fine-gauge needles, and alcohol swabs — nothing else to buy.
A titration schedule
A clear, conservative ramp so your body adjusts gently, week by week.
Cold-chain packaging
Temperature-controlled shipping keeps your protocol stable from our lab to your fridge.
Step-by-step guide
Plain-language instructions and short videos for confident, correct self-administration.
Direct care access
Message our clinical team any time with questions about your protocol or progress.
The science
A new class of metabolic medicine
Triple-agonist peptides engage three hormonal pathways at once. The published research on this class is among the most promising in metabolic health.
3 receptors
GLP-1, GIP and glucagon are engaged together — addressing appetite, insulin response and energy expenditure in one molecule.
Coskun T, et al. LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist. Cell Metabolism, 2022.
Weekly
A single weekly subcutaneous dose — designed to fit real life, not a clinic schedule.
Rosenstock J, et al. Retatrutide in type 2 diabetes: phase 2 trial. The Lancet, 2023.
Glucagon
Adding glucagon-receptor activity may increase energy expenditure beyond appetite suppression alone.
Müller TD, et al. Glucagon-based therapeutics. Nature Reviews Drug Discovery, 2022.
What members are working toward
Metabolic health
Support healthier blood-sugar response and insulin sensitivity over time.
Sustainable weight
Reduce appetite and cravings so progress compounds week over week.
Energy & focus
Many members report steadier energy as their metabolism rebalances.
Confidence
Visible, measurable change you can feel — without a clinic schedule.
Longevity markers
Better weight and glucose control are linked to long-term health.
Everyday simplicity
One weekly dose, clear instructions, and a team a message away.
Is this right for me?Serious medicine,
Serious medicine,
handled with care.
Peptide therapy is powerful — and that means it deserves real oversight. Here’s how we keep Reta1 safe, honest, and human.
A clinician reviews every request
Reta1 isn't right for everyone. A licensed clinician reviews your intake and confirms eligibility before anything ships.
Conservative, transparent dosing
We start low and titrate slowly to minimize side effects. You'll always know exactly what you're taking and why.
Support that doesn't disappear
Our care team is one message away throughout your protocol. Big change is easier when you're never doing it alone.
Start my plan
Start your protocol, shipped to your door.
Join the 12,000+ people on their Reta1 protocol. Start your plan, complete a short clinician-reviewed intake, and we’ll take it from there.